Notably, CRISPR-Gold targeting of the metabotropic glutamate receptor 5 (mGluR5) gene significantly reduced mGluR5 levels in the striatum, and was shown to reverse repetitive behaviors in a mouse model of fragile X syndrome (a form of autism spectrum disorder) [67]. The gene discussed is GRM5; the disease is fragile X syndrome.